Apnimed's IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug
Apnimed's IPO bags $192M for what could become the first oral sleep apnea drug; proceeds will support the regulatory process and launch plans for Oxnimbi.
Apnimed
Private
Apnimed is a clinical-stage pharmaceutical company developing pharmacologic treatments for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. Lead candidate AD109 (Oxnimbi) is a once-nightly oral combination (atomoxetine + aroxybutynin) that targets the underlying cause of upper airway collapse. Apnimed reported two Phase 3 wins in 2025 and has filed for FDA approval.
Company Info
Sector:Sleep / CNS
Headquarters:Cambridge, Massachusetts, USA
Founded:2017
Website:apnimed.com
Funding Round:See funding history at company website
Total Funding:See company disclosures
Funding & Investor Relations
IPO Outlook / Plans
TBD
Recent News
Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch
Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch
Apnimed’s IPO dream comes true with upsized $192M IPO
Apnimed’s IPO dream comes true with upsized $192M IPO
Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA)
/PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral...
Apnimed dreams of IPO to fund launch of sleep apnea pill
Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision. The therapy, called Oxnimbi or AD109, is a drug combination that targets a cause of upper airway collapse in people with OSA. Apnimed reported two phase 3 wins for AD109 in 2025 and submitted an approval application to the FDA in April this year.
Leadership Team
TBD
CEO
Careers & Job Openings